In a filing, Xeris Biopharma Holdings Inc revealed its insider McCulloch Kevin unloaded Company’s shares for reported $0.12 million on Jan 08 ’26. In the deal valued at $8.00 per share,15,000 shares were sold. As a result of this transaction, McCulloch Kevin now holds 1,685,426 shares worth roughly $12.99 million.
Then, KEVIN MCCULLOCH bought 60,000 shares, generating $432,600 in total proceeds.
Before that, Shannon John Patrick Jr sold 24,907 shares. Xeris Biopharma Holdings Inc shares valued at $176,257 were divested by the insider at a price of $7.08 per share. As a result of the transaction, Shannon John Patrick Jr now holds 2,705,346 shares, worth roughly $20.86 million.
Barclays initiated its Xeris Biopharma Holdings Inc [XERS] rating to an Overweight in a research note published on December 09, 2025; the price target was $9. Piper Sandler also remained covering XERS and has decreased its forecast on November 11, 2024 with a “Neutral” recommendation from previously “an Overweight” rating. Oppenheimer started covering the stock on March 28, 2024. It rated XERS as “an Outperform”.
Price Performance Review of XERS
On Tuesday, Xeris Biopharma Holdings Inc [NASDAQ:XERS] saw its stock fall -2.03% to $7.71. Over the last five days, the stock has gained 10.78%. Xeris Biopharma Holdings Inc shares have risen nearly 126.76% since the year began. Nevertheless, the stocks have fallen -1.78% over the past one year.
How much short interest is there in Xeris Biopharma Holdings Inc?
A steep rise in short interest was recorded in Xeris Biopharma Holdings Inc stocks on 2025-12-31, growing by 0.55 million shares to a total of 16.52 million shares. Yahoo Finance data shows the prior-month short interest on 2025-11-28 was 15.97 million shares. There was a rise of 3.32%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on August 28, 2023 when Craig Hallum began covering the stock and recommended ‘”a Buy”‘ rating along with a $4.50 price target.
